Bevacizumab treatment of prostate cancer

Alexander C. Small, William K. Oh

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Introduction: Angiogenesis plays an important role in the development and progression of prostate cancer. Vascular endothelial growth factor (VEGF) is a primary mediator of this process and is a target for novel therapies. Bevacizumab is a recombinant anti-VEGF monoclonal antibody that has demonstrated antitumor activity in a variety of cancers. Areas covered: In this review, we present the results of several clinical trials for bevacizumab in prostate cancer. Overall, these trials have shown improvements in progression-free survival but no changes in overall survival. Ongoing clinical trials are testing bevacizumab in combination with novel cytotoxic drugs and targeted therapies in metastatic and localized settings. Expert opinion: Bevacizumab has biological activity in prostate cancer. However, the mixed clinical trial results support the theory that prostate cancers may be driven only in part by angiogenesis. Questions remain about the future role of bevacizumab in the treatment of prostate cancer.

Original languageEnglish (US)
Pages (from-to)1241-1249
Number of pages9
JournalExpert opinion on biological therapy
Issue number9
StatePublished - Sep 2012
Externally publishedYes


  • Angiogenesis
  • Anti-VEGF
  • Bevacizumab
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Bevacizumab treatment of prostate cancer'. Together they form a unique fingerprint.

Cite this